Heron Therapeutics, Inc. (NASDAQ:HRTX) received a $31.00 price target from equities research analysts at Cantor Fitzgerald in a report issued on Friday. The firm presently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 103.28% from the stock’s current price.

A number of other analysts have also commented on the company. Zacks Investment Research lowered Heron Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 9th. Aegis reiterated a “buy” rating and set a $33.00 price target on shares of Heron Therapeutics in a report on Tuesday, July 18th. Noble Financial reiterated a “buy” rating on shares of Heron Therapeutics in a report on Friday, May 12th. Cowen and Company reiterated a “buy” rating and set a $40.00 price target on shares of Heron Therapeutics in a report on Friday, May 26th. Finally, ValuEngine upgraded Heron Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. One analyst has rated the stock with a sell rating and eleven have issued a buy rating to the stock. Heron Therapeutics presently has a consensus rating of “Buy” and an average target price of $31.00.

Shares of Heron Therapeutics (HRTX) opened at 15.25 on Friday. The firm has a 50-day moving average price of $15.50 and a 200 day moving average price of $14.65. Heron Therapeutics has a 1-year low of $12.21 and a 1-year high of $21.24.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.90) by $0.10. The business had revenue of $8.51 million for the quarter, compared to the consensus estimate of $4.53 million. Analysts forecast that Heron Therapeutics will post ($3.50) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Cantor Fitzgerald Analysts Give Heron Therapeutics, Inc. (HRTX) a $31.00 Price Target” was posted by Daily Political and is the property of of Daily Political. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.dailypolitical.com/2017/08/18/cantor-fitzgerald-analysts-give-heron-therapeutics-inc-hrtx-a-31-00-price-target.html.

Several hedge funds have recently modified their holdings of HRTX. Virginia Retirement Systems ET AL purchased a new stake in shares of Heron Therapeutics during the first quarter valued at about $459,000. Parametric Portfolio Associates LLC raised its stake in shares of Heron Therapeutics by 86.8% in the first quarter. Parametric Portfolio Associates LLC now owns 33,139 shares of the biotechnology company’s stock valued at $497,000 after buying an additional 15,394 shares during the last quarter. Swiss National Bank raised its stake in shares of Heron Therapeutics by 39.9% in the first quarter. Swiss National Bank now owns 72,600 shares of the biotechnology company’s stock valued at $1,089,000 after buying an additional 20,700 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Heron Therapeutics by 27.1% in the first quarter. Bank of New York Mellon Corp now owns 190,771 shares of the biotechnology company’s stock valued at $2,861,000 after buying an additional 40,657 shares during the last quarter. Finally, Falcon Point Capital LLC purchased a new stake in shares of Heron Therapeutics during the first quarter valued at about $501,000.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.